Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trivaid
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Trivaid is a trivalent live attenuated vaccine developed by Pharm Aid in collaboration with the Serum Institute of India. It is designed for the active immunization of children and adults against measles, mumps, and rubella. The vaccine is a lyophilized preparation containing the Edmonston-Zagreb strain of the measles virus, the Leningrad-Zagreb strain of the mumps virus, and the Wistar RA 27/3 strain of the rubella virus. These attenuated strains are grown in human diploid cells (MRC-5) or chick embryo fibroblast cells, depending on the component. Trivaid is intended to induce a robust immune response, including both humoral (antibody-mediated) and cellular immunity, mimicking a natural infection without causing the clinical disease. In the Russian market, it is often supplied in a pre-filled syringe (PFS) format for ease of administration.
- Brand names
- TrivaidТРИВЭЙДTrivaid MMR PFS
- Other names
- Measles, Mumps and Rubella Vaccine (Live)MMR Vaccine Pharm Aid
Beyond the preview
Go deeper on Trivaid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trivaid.